Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity, Measured with a Sensor
Kentaro Yano
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorSuzune Mita
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorKaori Morimoto
Department of Drug Absorption and Pharmacokinetics, Tohoku Pharmaceutical University, Sendai, Miyagi, 981-8558 Japan
Search for more papers by this authorTamami Haraguchi
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorHiroshi Arakawa
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorMiyako Yoshida
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorFumiyoshi Yamashita
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501 Japan
Search for more papers by this authorTakahiro Uchida
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorCorresponding Author
Takuo Ogihara
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Telephone: +81-27-352-1180; Fax: +81-27-352-1118; E-mail: [email protected]Search for more papers by this authorKentaro Yano
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorSuzune Mita
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorKaori Morimoto
Department of Drug Absorption and Pharmacokinetics, Tohoku Pharmaceutical University, Sendai, Miyagi, 981-8558 Japan
Search for more papers by this authorTamami Haraguchi
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorHiroshi Arakawa
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Search for more papers by this authorMiyako Yoshida
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorFumiyoshi Yamashita
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501 Japan
Search for more papers by this authorTakahiro Uchida
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, 663-8179 Japan
Search for more papers by this authorCorresponding Author
Takuo Ogihara
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, 370-0033 Japan
Telephone: +81-27-352-1180; Fax: +81-27-352-1118; E-mail: [email protected]Search for more papers by this authorAbstract
P-glycoprotein (P-gp) regulates absorption of many drugs in the gastrointestinal tract and their accumulation in tumor tissues, but the basis of substrate recognition by P-gp remains unclear. Bitter-tasting phenylthiocarbamide, which stimulates taste receptor 2 member 38 (T2R38), increases P-gp activity and is a substrate of P-gp. This led us to hypothesize that bitterness intensity might be a predictor of P-gp-inhibitor/substrate status. Here, we measured the bitterness intensity of a panel of P-gp substrates and nonsubstrates with various taste sensors, and used multiple linear regression analysis to examine the relationship between P-gp-inhibitor/substrate status and various physical properties, including intensity of bitter taste measured with the taste sensor. We calculated the first principal component analysis score (PC1) as the representative value of bitterness, as all taste sensor's outputs shared significant correlation. The P-gp substrates showed remarkably greater mean bitterness intensity than non-P-gp substrates. We found that Km value of P-gp substrates were correlated with molecular weight, log P, and PC1 value, and the coefficient of determination (R2) of the linear regression equation was 0.63. This relationship might be useful as an aid to predict P-gp substrate status at an early stage of drug discovery. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2789–2794, 2015
REFERENCES
- 1Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T. 2013. Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo. J Pharm Sci 102(8): 2875–2881.
- 2Mottino AD, Catania VA. 2008. Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents. World J Gastroenterol 14(46): 7068–7074.
- 3Kneuer C, Honscha W, Gabel G, Honscha KU. 2007. Adaptive response to increased bile acids: Induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch 454(4): 587–594.
- 4Yano K, Takimoto S, Motegi T, Tomono T, Hagiwara M, Idota Y, Morimoto K, Takahara A, Ogihara T. 2014. Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain. Drug Metab Pharmacokinet 29: 254–258.
- 5Watanabe T, Maeda K, Nakai C, Sugiyama Y. 2013. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: A simulation study. J Pharm Sci 102(9): 3196–3204.
- 6Yang C, Li Z, Zhang T, Liu F, Ruan J, Zhang Z. 2013. Transcellular transport of aconitine across human intestinal Caco-2 cells. Food Chem Toxicol 57: 195–200.
- 7Glendinning JI. 1994. Is the bitter rejection response always adaptive? Physiol Behav 56(6): 1217–1227.
- 8Kinnamon SC. 2012. Taste receptor signalling—From tongues to lungs. Acta Physiologica 204(2): 158–168.
- 9Kaji I, Karaki S, Fukami Y, Terasaki M, Kuwahara A. 2009. Secretory effects of a luminal bitter tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine. Am J Physiol Gastrointest Liver Physiol 296(5): G971–G981.
- 10Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJ, Zuker CS. 2000. A novel family of mammalian taste receptors. Cell 100(6): 693–702.
- 11Jeon TI, Seo YK, Osborne TF. 2011. Gut bitter taste receptor signalling induces ABCB1 through a mechanism involving CCK. Biochem J 438(1): 33–37.
- 12Uchida T, Yoshida M, Hazekawa M, Haraguchi T, Furuno H, Teraoka M, Ikezaki H. 2013. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor. J Pharm Pharmacol 65(9): 1312–1320.
- 13Harada T, Uchida T, Yoshida M, Kobayashi Y, Narazaki R, Ohwaki T. 2010. A new method for evaluating the bitterness of medicines in development using a taste sensor and a disintegration testing apparatus. Chem Pharm Bull 58(8): 1009–1014.
- 14Haraguchi T, Miyazaki A, Yoshida M, Uchida T. 2013. Bitterness evaluation of intact and crushed Vesicare orally disintegrating tablets using taste sensors. J Pharm Pharmacol 65(7): 980–987.
- 15Shintaku K, Arima Y, Dan Y, Takeda T, Kogushi K, Tsujimoto M, Nagata H, Satoh S, Tsukimori K, Nakano H, Hori S, Ohtani H, Sawada Y. 2007. Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. Drug Metab Dispos 35(5): 772–778.
- 16Ingels F, Deferme S, Destexhe E, Oth M, Van den Mooter G, Augustijns P. 2002. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int J Pharm 232(1–2): 183–192.
- 17Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. 2005. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314(3): 1059–1067.
- 18Ieiri I. 2012. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27(1): 85–105.
- 19Hosomi A, Nakanishi T, Fujita T, Tamai I. 2012. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PloS One 7(2): e30456.
- 20Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. 2002. The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 123(5): 1649–1658.
- 21Bauer B, Miller DS, Fricker G. 2003. Compound profiling for P-glycoprotein at the blood–brain barrier using a microplate screening system. Pharm Res 20(8): 1170–1176.
- 22Kobayashi Y, Habara M, Ikezazki H, Chen R, Naito Y, Toko K. 2010. Advanced taste sensors based on artificial lipids with global selectivity to basic taste qualities and high correlation to sensory scores. Sensors (Basel, Switzerland) 10(4): 3411–3443.
- 23Borgnia MJ, Eytan GD, Assaraf YG. 1996. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271(6): 3163–3171.
- 24Tachibana T, Kato M, Sugiyama Y. 2012. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values. Pharm Res 29(3): 651–668.
- 25Petri N, Tannergren C, Rungstad D, Lennernas H. 2004. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 21(8): 1398–1404.
- 26Kimura Y, Kioka N, Kato H, Matsuo M, Ueda K. 2007. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J 401(2): 597–605.
- 27Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR, Chu T, Prinssen EP. 2009. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 53(11): 4753–4761.
- 28Cho HJ, Choi MK, Lin H, Kim JS, Chung SJ, Shim CK, Kim DD. 2011. Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air–liquid interface method for nasal drug transport study. J Pharm Pharmacol 63(3): 385–391.
- 29Ogihara T, Matsumoto S, Ohnishi S. 2004. Functional characterization of active transport of progesterone to adrenal cells. J Pharm Pharmacol 56(1): 79–84.
- 30Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. 2006. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34(12): 1976–1984.
- 31Didziapetris R, Japertas P, Avdeef A, Petrauskas A. 2003. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 11(7): 391–406.